Physician profile
Steven Giang
NPI 1730710104
$6,130.32
in general payments reported to CMS, 2019-2025
21 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $532 · 2021: $1,687 · 2022: $1,117 · 2023: $1,218 · 2024: $1,403 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,551 · Entertainment: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,550.75 |
| Entertainment | $243.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,431.86 | 2022-2025 | Infuse, Ultra Multifocal Toric, Miebo |
| Alcon Vision LLC | $1,095.63 | 2021-2025 | Total30, Dailies, Clareon |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,011.00 | 2020-2021 | |
| Abbvie INC. | $594.36 | 2022-2025 | |
| Coopervision INC. | $451.14 | 2020-2024 | Myday Contact Lens |
| Optos, INC. | $342.49 | 2021-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Mallinckrodt Hospital Products INC. | $214.58 | 2022-2023 | Acthar |
| Glaukos Corporation | $181.02 | 2021-2023 | Photrexa Cross-Linking Kit |
| Sun Pharmaceutical Industries INC. | $149.27 | 2021 | |
| Lkc Technologies, INC. | $126.13 | 2024 | |
| Ocular Therapeutix, INC. | $125.00 | 2021 | |
| Kala Pharmaceuticals, INC. | $119.35 | 2021 | |
| Topcon Healthcare, INC. | $101.43 | 2020 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Dompe US, INC. | $34.37 | 2024 | Oxervate |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $25.70 | 2023 | Tyrvaya |
| Biotissue Holdings INC. | $20.12 | 2022 | |
| Horizon Therapeutics Plc | $19.06 | 2023 | Tepezza |
| Thea Pharma INC. | $17.08 | 2023 | |
| Novartis Pharmaceuticals Corporation | $16.63 | 2022 | |
| Abb Con-Cise Optical Group LLC | $15.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Giang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.